<DOC>
	<DOCNO>NCT02647255</DOCNO>
	<brief_summary>Crescentic IgA nephropathy ( CreIgAN ) poor prognosis despite aggressive immunosuppressive therapy . The efficacy plasma exchange ( PE ) CreIgAN well define . This study evaluate efficacy safety plasma exchange adjunctive therapy severe crescentic IgA nephropathy compare pulse methylprednisolone background oral prednisolone cyclophosphamide prevent kidney failure .</brief_summary>
	<brief_title>Trial Plasma Exchange Severe Crescentic IgA Nephropathy</brief_title>
	<detailed_description>IgA nephropathy ( IgAN ) one common glomerulonephritides characterize highly variable clinical course diverse histopathological lesion . Although affected individual develop chronic , slowly progressive renal injury , subgroup patient ( &lt; 5 % IgAN patient ) diffuse crescent formation , term crescentic IgA nephropathy ( CreIgAN ) often lead rapidly progressive kidney failure . The recent Kidney Disease : Improving Global Outcomes ( KDIGO ) guideline suggest high-dose steroid cyclophosphamide therapy CreIgAN . However , suggestion mainly base several small observational study , 1- 5-year renal survival rate patient treat regimen low 65 % 28 % , respectively , one large cohort CreIgAN patient . The efficacy plasma exchange ( PE ) severe CreIgAN well evaluate , although several anecdotal report indicate benefit PE combination immunosuppressive therapy IgAN patient . Retrospective cohort study unite also support benefit PE additional therapy CreIgAN patient . However , randomize control trial need evaluate efficacy safety plasma exchange adjunctive therapy crescentic IgA nephropathy compare pulse methylprednisolone background oral prednisolone cyclophosphamide prevent kidney failure .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Biopsyproven within 3ws 2 . Primary IgAN HenochSchönlein Purpura nephritis crescent &gt; 50 % ( &gt; 8 glomerulus ) 3 . Serum creatinine ≥ 200 μmol/l， rapidly deterioration renal function 1 . &lt; 14 &gt; 65 year old 2 . With high Scr require dialysis for≥ 3w 3 . Scr &gt; 200μmol/L ≥1 yr entry 4 . Main old crescent ; Fibrous crescent &gt; 50 % 5 . Antiglomerular basement membrane ( GBM ) antineutrophil cytoplasmic antibody ( ANCA ) antibody positive 6 . Women gestational lactational period 7 . With diabetes uncontrollable malignant hypertension Thrombotic Microangiopathy 8 . With Malignancy 9 . Chronic active infection include HBV hepatitis C virus ( HCV ) HIV active tuberculosis 10 . Other autoimmune disease 11 . A second clearly define cause renal failure 12 . Contraindication plasma exchange treatment steroid pulse 13 . Patients unlikely comply study protocol view treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>crescentic IgA nephropathy</keyword>
	<keyword>plasma exchange treatment plasmapheresis</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>intensive immunosuppressive treatment</keyword>
	<keyword>methylprednisolone pulse</keyword>
</DOC>